Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study
ConclusionASP3026 at a 200-mg dose may provide therapeutic benefit for patients with solid tumors, with a tolerable safety profile.Clinical Trial registrationThis study is registered at ClinicalTrials.gov under the identifier NCT01401504 on July 25, 2011
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Bone Cancers | Cataracts | Clinical Trials | Drugs & Pharmacology | Ewing's Sarcoma | Genetics | Japan Health | Lymphoma | Sarcomas | Study | Toxicology